Publication:
Comparison of Somatostatin Analogue (SA) and Chemotherapy (CT) in Neuroendocrine Tumors (NET) Patients with Ki-67 <= 20%

Simple item page
dc.contributor.authorsOzaslan, E.; Koca, S.; Sevinc, A.; Hacioglu, B.; Ozcelik, M.; Duran, A. O.; Yildiz, Y.; Tanriverdi, O.; Menekse, S.; Aksoy, A.; Elmaci, S.; Uysal, M.; Ciltas, A.
dc.date.accessioned2022-03-12T16:16:56Z
dc.date.accessioned2026-01-10T20:22:11Z
dc.date.available2022-03-12T16:16:56Z
dc.date.issued2016
dc.identifier.doidoiWOS:000386481600195
dc.identifier.eissn1423-0194
dc.identifier.issn0028-3835
dc.identifier.urihttps://hdl.handle.net/11424/225853
dc.identifier.wosWOS:000386481600195
dc.language.isoeng
dc.publisherKARGER
dc.relation.ispartofNEUROENDOCRINOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectSomatostatin analogue
dc.subjectNET
dc.subjectKi-67
dc.titleComparison of Somatostatin Analogue (SA) and Chemotherapy (CT) in Neuroendocrine Tumors (NET) Patients with Ki-67 <= 20%
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage74
oaire.citation.startPage74
oaire.citation.titleNEUROENDOCRINOLOGY
oaire.citation.volume103

Files

Collections

Araştırma Çıktıları